Diagnostic catheters, transradial product suite cleared, made available

Medtronic announced that, following FDA and CE mark clearance, a new angiography catheter line and several transradial-access-specific products for PCI and diagnostic catheterization procedures are now available.

The diagnostic catheters (DxTerity and DxTerity TRA) are used to determine the necessity of revascularization in patients with CAD, according to a press release issued by the company.

The DxTerity TRA catheters are designed for transradial access and allow for engagement of both coronary arteries without the exchange of catheters, according to the release.

Also now available are a transradial access kit (InTRAkit) of needles, mini guidewires and introducer sheaths; and a compression device (TRAcelet) to promote access-site patent hemostasis, the company stated in the release.

"The global approval of the DxTerity Diagnostic Catheters, as well as the introduction of the new Medtronic suite of transradial products represents a significant step forward for patients requiring PCI procedures," Sunil V. Rao, MD, FSCAI, FACC, interventional cardiologist and associate professor of medicine at Duke University and a member of the Cardiology Today’s Intervention Editorial Board, said in the release. "It's increasingly important to have a full suite of products accompanied by robust training to increase physician utilization, improve patient comfort and enable same-day discharge."

Sunil V. Rao

According to the release, also newly available is a fully customizable education and training program for physicians, staff and administrators to ensure successful adoption of the transradial approach from access to patent hemostasis (Transradial Arc Curriculum).

Using a hospital-specific approach, the curriculum is designed to provide clinical training and better patient care pathways to help institutions optimize the delivery of transradial care, according to the release.

Disclosure: Rao reports consulting for Medtronic.